

INTEST CORP  
Form SD  
May 31, 2018  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form SD**

**Specialized Disclosure Report**

**inTEST Corporation**

(Exact Name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**1-36117**

(Commission File Number)

**22-2370659**

(I.R.S. Employer  
Identification No.)

**804 East Gate Drive, Suite 200**

**Mt. Laurel, New Jersey**

(Address of principal executive offices)

**08054**

(Zip Code)

**Hugh T. Regan, Jr., (856) 505-8800**

(Name and telephone number, including area code, of the person to contact in connection with this report)

Edgar Filing: INTEST CORP - Form SD

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2017

---

## **Section 1 - Conflict Minerals Disclosure**

### **Item 1.01 Conflict Minerals Disclosure and Report**

This Form SD for inTEST Corporation (the "Company") is being filed pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2017 to December 31, 2017. The Company conducted an analysis of its products and determined that all of its products (the "Covered Products") contained one or more "conflict minerals" as defined in Item 1.01(d)(3) of Form SD. After conducting due diligence, the Company concluded that it could not yet determine whether or not the conflict minerals in the Covered Products originated in the Democratic Republic of the Congo or an adjoining country, as defined in Item 1.01(d)(1) of Form SD, or whether the conflict minerals were from recycled or scrap sources or were or were not from other conflict free sources. Consequently, we determined that these products are "DRC conflict undeterminable" as defined in Item 1.01(d)(5) of Form SD.

#### Conflict Minerals Disclosure

The Company is filing herewith as Exhibit 1.01 its Conflict Minerals Report. The Conflict Minerals Report is publicly available at [www.intest.com](http://www.intest.com) under "About - Conflict Minerals Report".

### **Item 1.02 Exhibit**

A copy of the Company's Conflict Minerals Report is filed as Exhibit 1.01 hereto.

## **Section 2 – Exhibits**

### **Item 2.01 Exhibits**

The following exhibit is filed as required by Items 1.01 and 1.02 of this Form SD.

**Exhibit No. Description**

1.01 Conflict Minerals Report of inTEST Corporation

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

**inTEST CORPORATION**

By: /s/ Hugh T. Regan, Jr.  
Hugh T. Regan, Jr.

Date: May 31, 2018

Secretary, Treasurer and Chief Financial Officer

Common Stock02/26/2009 S 875 D \$ 26 18,989 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 236 D \$ 25.89  
18,753 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 48 D \$ 25.88 18,705 I See Footnote <sup>(6)</sup> Common  
Stock02/26/2009 S 95 D \$ 25.87 18,610 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 109 D \$ 25.86 18,501 I  
See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 1,058 D \$ 25.85 17,443 I See Footnote <sup>(6)</sup> Common Stock02/26/2009  
S 142 D \$ 25.84 17,301 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 95 D \$ 25.83 17,206 I See Footnote <sup>(6)</sup>  
Common Stock02/26/2009 S 48 D \$ 25.82 17,158 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 377 D \$ 25.81  
16,781 I See Footnote <sup>(6)</sup> Common Stock02/26/2009 S 2,351 D \$ 25.8 14,430 I See Footnote <sup>(6)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

Edgar Filing: INTEST CORP - Form SD

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MIDDLETON FRED A 227 WASHINGTON STREET, #300 CONSHOHOCKEN, PA 19428		X		

**Signatures**

/s/ Catherine A. Petko, by power of attorney  
 Date: 03/02/2009  
 \*\*Signature of Reporting Person

**Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pro rata distribution of shares of common stock to limited partners.  
 By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (2) By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (3) By Sanderling Venture Partners VI Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil, Mills & Associates VI, LLC the sole general partner of Sanderling Venture Partners VI Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners VI Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- (4) Fred Middleton, a member of the Issuer's board of directors, received a distribution of shares of common stock as a limited partner of the following entities: Sanderling V Biomedical Co-Investment Fund L.P.; Sanderling Venture Partners V Co-Investment Fund, L.P; and Sanderling Venture Partners VI Co-Investment Fund, L.P..

## Edgar Filing: INTEST CORP - Form SD

- (6) By Sanderling V Beteiligungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteiligungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteiligungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.